WCM
SRNE

Wildcat Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Wildcat Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-23,610
Closed -$38K – 24
2015
Q3 		$38K Buy
+23,610
New +$376K 0.01% 20

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wildcat Capital Management's SRNE Position: Q3 2019 in Review

Wildcat Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2019, closing a stake of 415,765 shares — an estimated $1.11M sold.

Wildcat Capital Management first reported a position in SRNE in Q2 2015 and held it in 17 quarters. The position peaked at $22.9M in Q4 2015. 85 funds tracked by Wall St. Rank hold SRNE as of Q3 2019.

  • Wildcat Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Wildcat Capital Management sold 415,765 Sorrento Therapeutics, Inc. shares in Q3 2019, an estimated $1.11M.
  • Wildcat Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 17 quarters.
  • Wildcat Capital Management's Sorrento Therapeutics, Inc. position peaked at $22.9M in Q4 2015.
  • 85 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2019.

Based on Wildcat Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.